VALN
Valneva SE - ADR

2,103
Mkt Cap
$887.98M
Volume
757,956.00
52W High
$12.25
52W Low
$5.43
PE Ratio
-6.63
VALN Fundamentals
Price
$6.50
Prev Close
$10.32
Open
$6.73
50D MA
$10.28
Beta
0.95
Avg. Volume
20,751.94
EPS (Annual)
-$1.55
P/B
7.18
Rev/Employee
$292,457.41
$856.29
Loading...
Loading...
News
all
press releases
Valneva (NASDAQ:VALN) Sees Large Volume Increase - Here's Why
Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Still a Buy...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Pfizer: Lyme Disease Vaccine Candidate Shows Strong Efficacy In Phase 3 VALOR Trial
(RTTNews) - Pfizer (PFE) and Valneva SE (VALN) announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor Recreationists trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrating: in the pre-specified analyses...
Nasdaq News: Markets·9h ago
News Placeholder
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor Recreationists clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V...
Business Wire·10h ago
News Placeholder
HC Wainwright Has Positive Forecast for Valneva Q3 Earnings
Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Valneva in a research note issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per...
MarketBeat·15h ago
News Placeholder
Valneva (NASDAQ:VALN) Shares Gap Down - Here's What Happened
Valneva (NASDAQ:VALN) Shares Gap Down - What's Next...
MarketBeat·3d ago
News Placeholder
FY2030 Earnings Estimate for Valneva Issued By HC Wainwright
Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) - Equities research analysts at HC Wainwright reduced their FY2030 earnings per share (EPS) estimates for shares of Valneva in a report issued on...
MarketBeat·3d ago
News Placeholder
Valneva Q4 Earnings Call Highlights
Valneva (NASDAQ:VALN) executives highlighted steady full-year 2025 revenue, tighter cash discipline, and multiple clinical and commercial catalysts during the company's results and business update call. Management reiterated that upcoming pivotal phase 3 data for its Lyme disease vaccine candidate...
MarketBeat·5d ago
News Placeholder
Valneva (NASDAQ:VALN) Shares Gap Up - Still a Buy?
Valneva (NASDAQ:VALN) Shares Gap Up - Here's Why...
MarketBeat·5d ago
News Placeholder
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program PR Newswire VIENNA...
PR Newswire·5d ago
News Placeholder
Valneva FY25 Net Loss Widens, Product Sales Down; Sees Lower Revenues In FY26
(RTTNews) - French biotech company Valneva SE (VALN, VLA.PA, VLA.VI) reported Wednesday wider net loss in fiscal 2025, mainly on the absence of prior year's gain and lower product sales...
Nasdaq News: Markets·6d ago
<
1
2
...
>

Latest VALN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.